SEI Investments’s Protalix BioTherapeutics PLX Stock Holding History

SEI Investments’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-321	Closed	-$1K	–	3186
2018 Q2	$1K	Hold	321	–	–	﹤0.01%	3501
2018 Q1	$2K	Hold	321	–	–	﹤0.01%	3257
2017 Q4	$2K	Hold	321	–	–	﹤0.01%	3127
2017 Q3	$2K	Hold	321	–	–	﹤0.01%	2995
2017 Q2	$3K	Buy	+321	New	+$3.01K	﹤0.01%	2820

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SEI Investments's PLX Position: Q3 2018 in Review

SEI Investments sold out of Protalix BioTherapeutics (PLX) in Q3 2018, closing a stake of 321 shares — an estimated $1K sold.

SEI Investments first reported a position in PLX in Q2 2017 and held it in 5 quarters. The position peaked at $3K in Q2 2017. 38 funds tracked by Wall St. Rank hold PLX as of Q3 2018.

SEI Investments reported no remaining Protalix BioTherapeutics position as of Q3 2018 after selling out during the quarter.
SEI Investments sold 321 Protalix BioTherapeutics shares in Q3 2018, an estimated $1K.
SEI Investments first reported a position in Protalix BioTherapeutics in Q2 2017 and held it in 5 quarters.
SEI Investments's Protalix BioTherapeutics position peaked at $3K in Q2 2017.
38 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2018.

Based on SEI Investments's 13F filing for Q3 2018, filed 8 Nov 2018.